

### Scientific Division (SD)

### **Prof. Philippe GILLERY**

Service de Biochimie - Pharmacologie Toxicologie Pôle de Biologie Médicale et Pathologie CHU de Reims Pôle de Biologie Territoriale 51092 Reims Cedex - FRANCE E-mail: pgillery@chu-reims.fr

### Vice-Chair Prof. Christa M. COBBAERT

Clinical Chemist Head of the Department of Clinical Chemistry Leiden University Medical Center 2300 RC Leiden – THE NETHERLANDS E-mail: <u>C.M.Cobbaert@lumc.nl</u>

Prof. Garry JOHN
Department of Clinical Biochemistry and Immunology
Norfolk and Norwich University Hospital Norwich NR4 7UY - UK
E-mail: g.john@nhs.net

## Dr. Barnali DAS

Consultant, Laboratory Medicine Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute, Mumbai-400053 - INDIA E-mail: drbarnalid@gmail.com

### Dr. Konstantinos MAKRIS

Or. Konstantinos MAKKIS
Clinical Biochemistry Department
KAT General Hospital
Kifissia, Athens - GREECE
E-mail: kostas.makris.km@gmail

### Prof. Mario PLEBANI

Prof. Mario PLEBANI
Full Professor of Clinical Biochemistry and
Clinical Molecular Biology
Chief Department of Laboratory Medicine
University Hospital – Padova
Dean of the Medical School
University of Padova – ITALY
E-mail: mario.plebani@unipd.it

# Corporate Representative Dr. Michael ROTTMANN

Roche Diagnostics GmbH Director Assay Developmen Indication: Tyroid, Sepsis, RA, Growth Centralised and Point of Care solutions 82377 Penzberg - GERMANY

# Bureau International des Poids et

Dr. Ralf D. JOSEPHS

Principal Chemist Pavillon de Breteuil 92312 Sèvres Cedex - FRANCE E-mail: ralf.josephs@bipm.org

### European Commission -JRC Observe

Dr. Liesbet DEPREZ Project Officer Directorate General Joint Research Centre Reference Materials Unit 2440 Geel – BELGIUM E-mail: Liesbet.deprez@

# ICHCLR Observer

Prof. Ian S. YOUNG
Professor of Medicine
Queen's University Belfast
The Center for Public Health
1st floor - ICS B block
Royal Victoria Hospital
BT12 GBJ - Belfast - UK
E-mail: Young@gulb ac uk E-mail: I.Young@qub.ac.uk

# **JCTLM Consultant**

Pr. Greg MILLER
Professor of Pathology
Co-Director of Clinical Chemistry
Director of Pathology Information Systems
Virginia Commonwealth University Health System
Richmond, VA 23298-0286 - USA Email: greg.miller@vcuhealth.org

## **NIBSC Consultant**

Pr. Chris BURNS PhD
Head, Biotherapeutics Division
National Institute for Biological Standards and
Control - A Centre of the MHRA
Hertfordshire, EN6 3QG, UK
E-mail: Chris.Burns@nibsc.org

### NIFDC Observer Dr. Yang Zhen

Deputy Director Genera National Institutes for Food and Drug Controls (NIFDC) - P.R. CHINA

## **NIST Consultant**

Dr. Karen W. PHINNEY

Leader, Bioanalytical Science Grou Biomolecular Measurement Division National Institute of Standards and Technology (NIST)
Gaithersburg, MD 20899-8314 - USA
E-mail: karen.phinney@nist.gov

Prof. Philippe Gillery - IFCC SD Chair From:

**Date January 17th, 2022** 

8.2.24 Call for Nominations for Membership of Committee on Ref:

Reference Intervals and Decision Limits (C-RIDL)

### All National Representatives of the Full and Affiliate Member Societies To: **All Corporate Members' Representatives**

Dear Colleagues,

In 2005, the IFCC established a Committee on Reference Intervals and Decision Limits (C-RIDL). Since then, the Committee has provided IFCC with high level expertise in the specific area of metrological traceability and standardization. The Committee, under the Chairmanship of Dr. Thomas Streichert, wishes to appoint two new members to substitute two officers who have completed the term of office. The time in office will begin next March.

The specific terms of reference of this Committee are:

- To review current concepts relating to the establishment of reference intervals and decision limits and to prepare state of the art position statements that respect the requirement of international directives, such as the European IVD Directive 98-79, and relevant Standards.
- To determine a priority list of measurands (analytes) for which reference intervals have to be studied considering various factors such as age, gender, ethnicity, and for which the greatest improvements in medical decision making are anticipated.
- To monitor and evaluate currently proposed reference intervals for selected measurands (analytes) in the light of the concept of traceability and of the quantification of the uncertainty.
- To establish transferability protocols for reference intervals and decision limits which take into consideration inter-laboratory method variations and which have the potential to achieve better applicability in clincal practice.
- To collaborate with other organizations working in the same field.
- To work in close collaboration with the other Committees and Working Groups of SD and other Divisions for the development and appropriate clinical utilization of reference intervals and decision limits.

The selected candidates will have a demonstrable expertise in the area of epidemiology, biostatistics of popolation studies, and, above all, they should be able to provide a practical contribution by actively participating in multicenter reference intervals studies. Nomination of a young scientist is welcome.

Nominations should be directly sent to the IFCC Office (paola.bramati@ifcc.org) using the attached Application Form, by February 20th, 2022.

The application must include:

- 1) Name, Institution address, telephone number and e-mail address of the nominee.
- 2) A full description of his/her professional career particularly highlighting the issues which could be important for his/her selection.
- 3) National Society's letter of support.

Following approval, the candidate will be appointed for a three-year term on the C-RIDL starting March 2022. A second three-year term is allowed following satisfactory review at the end of the first term by the SD Executive Committee following consultation with the C-RIDL Chair.

Looking forward to receiving your nomination, I remain

Yours sincerely

Prof. Philippe Gillery, MD, PhD

Chair IFCC Scientific Division